Equities research analysts at Lazard Capital initiated coverage on shares of AVI BioPharma (NASDAQ: AVII) in a research note issued to investors on Thursday. They set a “buy” rating and a $5.00 price target on the stock. Lazard Capital Markets is full service broker-dealer. Lazard’s Capital research covers the following Healthcare (BioPharma) companies: Aegerion NeurogesX Alkermes […]